89bio to present at the 42nd annual raymond james institutional investors conference

San francisco, feb. 24, 2021 (globe newswire) -- 89bio, inc. (nasdaq: etnb), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that company's management will provide a corporate update and participate in one-on-one investor meetings at the raymond james 42nd annual institutional investors conference on wednesday, march 3, 2021 at 12:30 pm et.
ETNB Ratings Summary
ETNB Quant Ranking